Statin use and mortality within 180 days after bacteremia: a population-based cohort study.
OBJECTIVE
To examine the association between preadmission statin use and mortality among patients with bacteremia in a population-based setting.


METHODS
Observational study based on prospective registration of bacteremia episodes and mortality over a 6-yr period.


METHODS
North Jutland County, Denmark (population, 500,000).


METHODS
A total of 5,353 adult patients hospitalized with bacteremia from 1997 to 2002. Individuals treated with statins (n = 176) were identified by record-linkage with the County Prescription Database.


METHODS
None.


RESULTS
We compared mortality rates 0-30 and 31-180 days after bacteremia in patients with and without preadmission statin use, adjusted for gender, age group, level of comorbidity, alcohol-related conditions, use of immunosuppressive drugs and systemic antibiotics, and focus on infection. The 30-day mortality in statin users vs. nonusers was similar (20.0% vs. 21.6%, adjusted mortality rate ratio 0.93, 95% confidence interval 0.66-1.30). Among survivors after 30 days, however, statin therapy was associated with a substantially decreased mortality up until 180 days after the bacteremia (8.4% vs. 17.5%, adjusted mortality rate ratio 0.44, 95% confidence interval 0.24-0.80). This tendency toward similar short-term and decreased longer term mortality associated with statin use was observed consistently in both community-acquired and nosocomial bacteremia episodes and when analyses were restricted to patients with previous cardiovascular discharge diagnoses or diabetes.


CONCLUSIONS
This study provides evidence against the hypothesis that statin use has an effect on short-term mortality after bacteremia. Statin use was, however, associated with a substantially decreased mortality between 31 and 180 days after bacteremia.
Thomsen
Reimar W
RW
Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark.
Hundborg
Heidi H
HH
Johnsen
Søren P
SP
Pedersen
Lars
L
Sørensen
Henrik T
HT
Schønheyder
Henrik C
HC
Lervang
Hans-Henrik
HH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016470:Bacteremia / Q000188:drug therapy* / Q000401:mortality*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors